{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:04:30Z","timestamp":1747163070525,"version":"3.40.5"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.intimp.2024.113029","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T20:21:48Z","timestamp":1725049308000},"page":"113029","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PA","title":["Prolyl hydroxylase inhibitor desidustat attenuates autoimmune hemolytic anemia in mice"],"prefix":"10.1016","volume":"142","author":[{"given":"Vishal J.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0723-4371","authenticated-orcid":false,"given":"Amit A.","family":"Joharapurkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samadhan G.","family":"Kshirsagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maulik S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hardikkumar H.","family":"Savsani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan H.","family":"Rakhasiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harshad S.","family":"Dodiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukul R.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.113029_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12979-020-00208-7","article-title":"Autoimmune hemolytic anemia: current knowledge and perspectives","volume":"17","author":"Michalak","year":"2020","journal-title":"Immunity Ageing"},{"key":"10.1016\/j.intimp.2024.113029_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm9123859","article-title":"New insights in autoimmune hemolytic anemia: from pathogenesis to therapy stage 1","volume":"9","author":"Barcellini","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.intimp.2024.113029_b0015","unstructured":"M.MATLOOB. ALAM, PRACTICAL GUIDE I PEDIATRIC HEMATOLOGY, First edit, MUHAMMAD MATLOOB ALAM, 2022."},{"key":"10.1016\/j.intimp.2024.113029_b0020","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41577-023-00926-1","article-title":"A guide to complement biology, pathology and therapeutic opportunity","volume":"24","author":"Mastellos","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2024.113029_b0025","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231222","article-title":"Five decades of natural killer cell discovery","volume":"221","author":"Lanier","year":"2024","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2024.113029_b0030","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.3390\/ijms25084296","article-title":"Autoimmune hemolytic anemias: classifications, pathophysiology, diagnoses and management","volume":"25","author":"Loriamini","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.113029_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25084296","article-title":"Autoimmune hemolytic anemias: classifications, pathophysiology, diagnoses and management","volume":"25","author":"Loriamini","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.113029_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1228142","article-title":"Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps","volume":"14","author":"Mulder","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113029_b0045","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000366244","article-title":"The effect of erythropoiesis-stimulating agents in patients with therapy-refractory autoimmune hemolytic anemia","volume":"41","author":"Salama","year":"2014","journal-title":"Transfus. Med. Hemother."},{"key":"10.1016\/j.intimp.2024.113029_b0050","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.ackd.2008.12.008","article-title":"Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?","volume":"16","author":"Kalantar-Zadeh","year":"2009","journal-title":"Adv. Chronic Kidney Dis."},{"key":"10.1016\/j.intimp.2024.113029_b0055","doi-asserted-by":"crossref","unstructured":"A.A. Joharapurkar, V.B. Pandya, V.J. Patel, R.C. Desai, M.R. Jain, Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases, 61 (2018) 6964\u20136982. https:\/\/pubmed.ncbi.nlm.nih.gov\/29712435\/ (accessed June 17, 2022).","DOI":"10.1021\/acs.jmedchem.7b01686"},{"key":"10.1016\/j.intimp.2024.113029_b0060","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000523949","article-title":"Desidustat in anemia due to dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-D)","volume":"53","author":"Gang","year":"2022","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.intimp.2024.113029_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100102","article-title":"Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state","volume":"3","author":"Joharapurkar","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"10.1016\/j.intimp.2024.113029_b0070","doi-asserted-by":"crossref","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","article-title":"The arrive guidelines 2.0: updated guidelines for reporting animal research","volume":"18","author":"du Sert","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.intimp.2024.113029_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.116832","article-title":"HIF-PHD inhibitor desidustat ameliorates iron deficiency anemia","volume":"483","author":"Patel","year":"2024","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113029_b0080","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/1871525716666180118152158","article-title":"Coagonist of GLP-1 and glucagon receptor ameliorates development of non-alcoholic fatty liver disease","volume":"16","author":"Patel","year":"2018","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"10.1016\/j.intimp.2024.113029_b0085","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.exphem.2017.02.003","article-title":"Pharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease","volume":"50","author":"Jagadeeswaran","year":"2017","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.intimp.2024.113029_b0090","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1182\/bloodadvances.2023012297","article-title":"Add-on erythropoietin in autoimmune hemolytic anemia","volume":"8","author":"Moser","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2024.113029_b0095","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3324\/haematol.2020.250522","article-title":"Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study","volume":"106","author":"Fattizzo","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.intimp.2024.113029_b0100","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1182\/bloodadvances.2023011798","article-title":"Recombinant erythropoietin in autoimmune hemolytic anemia with inadequate bone marrow response: a prospective analysis","volume":"8","author":"Fattizzo","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.intimp.2024.113029_b0105","article-title":"Roxadustat: not just for anemia","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113029_b0110","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejphar.2018.11.023","article-title":"Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation","volume":"843","author":"Jain","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113029_b0115","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/ddr.21792","article-title":"Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress","volume":"82","author":"Joharapurkar","year":"2021","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.intimp.2024.113029_b0120","article-title":"HIF stabilizer desidustat protects against complement-mediated diseases","author":"Patel","year":"2024","journal-title":"Drug Res."},{"key":"10.1016\/j.intimp.2024.113029_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166878","article-title":"Identification of stages of erythroid differentiation in bone marrow and erythrocyte subpopulations in blood circulation that are preferentially lost in autoimmune hemolytic anemia in mouse","volume":"11","author":"Chatterjee","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2024.113029_b0130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1055\/s-0035-1554630","article-title":"Pharmacological characterization of ZYAN1, a novel prolyl hydroxylase inhibitor for the treatment of anemia","volume":"66","author":"Jain","year":"2015","journal-title":"Drug Res."},{"key":"10.1016\/j.intimp.2024.113029_b0135","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/635670","article-title":"Clinical applications of hemolytic markers in the differential diagnosis and Management of Hemolytic Anemia","volume":"2015","author":"Barcellini","year":"2015","journal-title":"Dis. Markers"},{"key":"10.1016\/j.intimp.2024.113029_b0140","doi-asserted-by":"crossref","unstructured":"M. Zhao, L. Chen, J. Yang, Z. Zhang, H. Wang, Z. Shao, X. Liu, L. Xing, Interleukin 6 exacerbates the progression of warm autoimmune hemolytic anemia by influencing the activity and function of B cells, Scientific Reports 2023 13:1 13 (2023) 1\u201311. https:\/\/doi.org\/10.1038\/s41598-023-40239-w.","DOI":"10.1038\/s41598-023-40239-w"},{"key":"10.1016\/j.intimp.2024.113029_b0145","doi-asserted-by":"crossref","first-page":"1180509","DOI":"10.3389\/fimmu.2023.1180509","article-title":"The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket?","volume":"14","author":"Berentsen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113029_b0150","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/bcp.13970","article-title":"Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases","volume":"85","author":"Pan","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113029_b0155","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/07853890.2022.2157475","article-title":"Iron metabolism abnormalities in autoimmune hemolytic anemia and jianpishengxue keli can ameliorate hemolysis and improve iron metabolism in AIHA mouse models","volume":"55","author":"Zhao","year":"2023","journal-title":"Ann. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924015509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924015509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T02:53:02Z","timestamp":1728010382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924015509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":31,"alternative-id":["S1567576924015509"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113029","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolyl hydroxylase inhibitor desidustat attenuates autoimmune hemolytic anemia in mice","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113029"}}